12 November 2020 

Sagent Pharmaceuticals, a subsidiary of the Nichi-Iko Group, announced the launch its Phase II trial of Camostat Mesilate (Camostat) to test its efficacy and safety for treating high-risk Covid-19 patients. The company has begun enrolling patients for the trial.

The Russian National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund announced that the Sputnik V vaccine, demonstrated 92% efficacy in its Phase III Covid-19 trials. The studies enrolled 40,000 volunteers in Russia.

Pfizer and BioNTech signed an agreement to supply 200 million doses of its BNT162b2 mRNA-based vaccine against Covid-19 to European Union (EU) member states. The agreement also allows the European Commission to request an additional 100 million doses of the vaccine. The vaccines are expected to be delivered by the end of 2020, after thorough clinical success and regulatory authorisation.

Mateon Therapeutics, a developer of TGF-β therapeutics, announced that it has entered into a definitive agreement with contract manufacturer Windlas Biotech to market the ARTIVeda, Mateon’s leading ethnobiology drug, to fight Covid-19. Early clinical studies have demonstrated the drug’s safety and efficacy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.